{"id":"oritavancin-injection","safety":{"commonSideEffects":[{"rate":"7-10%","effect":"Headache"},{"rate":"5-8%","effect":"Nausea"},{"rate":"3-5%","effect":"Infusion site reactions"},{"rate":"2-4%","effect":"Diarrhea"},{"rate":"2-3%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oritavancin binds to D-Ala-D-Ala peptidoglycan precursors and also interacts with the bacterial cell membrane, preventing proper cell wall formation. This dual mechanism of action makes it effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. The drug is bactericidal and has a long half-life allowing for single-dose administration.","oneSentence":"Oritavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to peptidoglycan precursors and disrupting cross-linking.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:58.930Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organisms including MRSA"}]},"trialDetails":[{"nctId":"NCT03761953","phase":"PHASE4","title":"Oritavancin for Staphylococcus Aureus Infections in Opioid Users","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2019-07-01","conditions":"Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oritavancin Injection","genericName":"Oritavancin Injection","companyName":"University of Pennsylvania","companyId":"university-of-pennsylvania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oritavancin Injection is a small molecule used to treat Staphylococcus Aureus Bacteremia and Staphylococcus Aureus Endocarditis. It is administered via injection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}